Key Points
- CEO Nello Mainolfi sold 30,000 shares on Feb. 25 at an average price of $90.26 for a total of $2,707,800, reducing his stake to 666,195 shares (a 4.31% decrease).
- Kymera missed quarterly expectations, reporting EPS of ($0.97) vs. a ($0.77) consensus and revenue of $2.87M vs. $14.8M, with revenue down 60.8% year‑over‑year.
Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) CEO Nello Mainolfi sold 30,000 shares of the stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $90.26, for a total transaction of $2,707,800.00. Following the completion of the transaction, the chief executive officer directly owned 666,195 shares in the company, valued at approximately $60,130,760.70. This represents a 4.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Nello Mainolfi also recently made the following trade(s):
- On Wednesday, December 31st, Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock. The stock was sold at an average price of $78.06, for a total transaction of $2,341,800.00.
- On Monday, December 8th, Nello Mainolfi sold 100,000 shares of Kymera Therapeutics stock. The shares were sold at an average price of $89.17, for a total value of $8,917,000.00.
Kymera Therapeutics Stock Performance
Shares of NASDAQ KYMR traded down $0.94 during trading hours on Thursday, reaching $89.74. 111,932 shares of the stock were exchanged, compared to its average volume of 751,343. The firm has a market capitalization of $6.46 billion, a price-to-earnings ratio of -25.09 and a beta of 2.21. The stock's fifty day simple moving average is $78.07 and its 200 day simple moving average is $64.68. Kymera Therapeutics, Inc. has a 52 week low of $19.44 and a 52 week high of $103.00.
Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by ($0.20). Kymera Therapeutics had a negative net margin of 674.81% and a negative return on equity of 32.92%. The firm had revenue of $2.87 million during the quarter, compared to the consensus estimate of $14.80 million. During the same quarter last year, the firm earned ($0.88) earnings per share. The business's revenue for the quarter was down 60.8% compared to the same quarter last year. Research analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.
Analyst Ratings Changes
KYMR has been the topic of several research reports. Weiss Ratings restated a "sell (d-)" rating on shares of Kymera Therapeutics in a research note on Thursday, January 22nd. UBS Group raised shares of Kymera Therapeutics to a "strong-buy" rating in a report on Thursday, December 4th. Royal Bank Of Canada raised their target price on shares of Kymera Therapeutics from $70.00 to $103.00 and gave the stock an "outperform" rating in a report on Tuesday, December 16th. Wells Fargo & Company lifted their price target on shares of Kymera Therapeutics from $69.00 to $116.00 and gave the company an "overweight" rating in a research report on Tuesday, December 9th. Finally, Leerink Partners boosted their price target on Kymera Therapeutics from $70.00 to $118.00 and gave the company an "outperform" rating in a research note on Monday, December 8th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Kymera Therapeutics currently has an average rating of "Buy" and an average price target of $117.00.
Get Our Latest Stock Analysis on Kymera Therapeutics
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in KYMR. Smartleaf Asset Management LLC lifted its stake in Kymera Therapeutics by 382.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company's stock worth $42,000 after purchasing an additional 424 shares during the last quarter. Larson Financial Group LLC increased its stake in shares of Kymera Therapeutics by 81.5% in the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company's stock valued at $44,000 after purchasing an additional 349 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of Kymera Therapeutics during the 4th quarter worth $63,000. PNC Financial Services Group Inc. lifted its position in shares of Kymera Therapeutics by 506.6% during the 2nd quarter. PNC Financial Services Group Inc. now owns 922 shares of the company's stock worth $40,000 after buying an additional 770 shares during the last quarter. Finally, Bessemer Group Inc. lifted its position in shares of Kymera Therapeutics by 652.0% during the 3rd quarter. Bessemer Group Inc. now owns 940 shares of the company's stock worth $53,000 after buying an additional 815 shares during the last quarter.
About Kymera Therapeutics
(
Get Free Report)
Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.
The company's pipeline emphasizes immunology and oncology.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
